ReviewNature2009
Targeting the ubiquitin system in cancer therapy.
Review in Nature, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 328 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
328 citing papers in PubMed.
- TRIM3 and the Ubiquitin Checkpoint: Reframing PD-L1 Stability in Non-small Cell Lung Cancer.Annals of surgical oncology · 2026Article
- Assessment of USP17 and TPT1 Expression in Primary and Matched Metastatic Tissue of Patients with High-Grade Serous Ovarian Carcinoma and the Relationship to Distant Metastasis.Diagnostics (Basel, Switzerland) · 2026Article
- Protein-Protein Interaction Stabilizers from MD Simulation-Derived Pharmacophores.Journal of chemical information and modeling · 2026Article
- WWP2 ubiquitin ligase promotes colorectal cancer progression by targeting p53 for degradation: an experimental study.Annals of surgical treatment and research · 2026Article
- Proteomic Analysis of Ubiquitination Modified Proteins in Brain Tissue of Rats at Different Times after Severe Traumatic Brain Injury.Molecular neurobiology · 2026Article
- A Ubiquitination-Related Gene Prognostic Signature and the Oncogenic Role of RNF149 in Nasopharyngeal Carcinoma: scRNAseq- Based Bioinformatics and Experimental Validation.Current medicinal chemistry · 2026Article
- USP10 stabilizes FOXM1 through KAT5-mediated acetylation to suppress cell senescence and promote melanoma malignant progression.International journal of biological sciences · 2026Article
- Targeting the proteasome in cancer therapy: development and future opportunities in natural products.Frontiers in pharmacology · 2026Review
- Research progress of DUB enzyme in breast cancer.Clinical and experimental medicine · 2025Review
- Targeting the Ubiquitin-Proteasome System for Cancer.MedComm · 2025Review
- FBXW11 inhibits tumorigenesis by ubiquitinating YB1 in hepatocarcinoma.Journal of cancer research and clinical oncology · 2025Article
- Serum carnitine and cancer risk: a Mendelian randomization study identifying pancreatic cancer as a modifiable metabolic target.Discover oncology · 2025Article
- Proteostasis signatures in human diseases.PLoS computational biology · 2025Article
- FBXO10 Drives Hepatocellular Carcinoma Proliferation via K63-Linked Ubiquitination and Stabilization of FRMPD1.Current issues in molecular biology · 2025Article
- Visualization analysis of breast cancer-related ubiquitination modifications over the past two decades.Discover oncology · 2025Article
- USP37 as a novel regulator of NRF2 protein stability and chemoresistance in HCC.Discover oncology · 2025Article
- FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation.Frontiers in immunology · 2025Article
- The role of ubiquitination in health and disease.MedComm · 2024Review
- FBXO2 promotes the progression of papillary thyroid carcinoma through the p53 pathway.Scientific reports · 2024Article
- Article
268 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitin system is a network of proteins dedicated to the ubiquitylation of cellular targets and the subsequent control of numerous cellular functions. The deregulation of components of this elaborate network leads to human pathogenesis, including the development of many types of tumour. Alterations in the ubiquitin system that occur during the initiation and progression of cancer are now being uncovered, and this knowledge is starting to be exploited for both molecular diagnostics and the development of novel strategies to combat cancer.
Indexed as
Identifiers
19325623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.